Some cancer-related genes are altered more often than others, and alterations in certain genes may be occurring more often in certain cancer types. ACTDrug®+ is a cancer genomic profiling service that precisely analyses well-selected cancer-related genes and provides personalized treatment options for patients with breast, lung and colorectal cancer.

Exploring various genetic alterations for more precise therapeutic implications ACTDrug+ is the most precise cancer genomic profiling test especially designed for patients with breast, lung or colorectal cancer. ACTDrug+ sequences 35 druggable genes and detects copy number variations to provide more treatment options for you

ACTDrug+ is most suitable for patients with solid tumors who are

■ Newly diagnosed with breast, lung or colorectal cancer

■ First time targeted therapy users

Sample types:

Typical tissue samples include FFPE (formalin-fixed and paraffin-embedded) tissue, excessive body fluids associated with cancers such as lung water or ascites, etc.

Turnaround time:

14 calendar days after samples are received